Hypolipidemic drugs can change the composition of rat brain lipids

Tohoku Journal of Experimental Medicine

Volumn 204, Issue 4, 2004, Pages 299-308

  Vecka, Marek ^a,b   Tvrzická, Eva ^a   Staňková, Barbora ^a   Novák, František ^a   Nováková, Olga ^a   Žák, Aleš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Brain; Fatty acid; Fibrate; Lipids; Statin

Indexed keywords

ANTILIPEMIC AGENT; CARDIOLIPIN; CERAMIDE; CHOLESTEROL; FENOFIBRATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEMBRANE LIPID; MEVINOLIN; PHOSPHATIDYLETHANOLAMINE; PLACEBO; POLYUNSATURATED FATTY ACID; PRAVASTATIN; SATURATED FATTY ACID; SPHINGOLIPID; SPHINGOMYELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; BRAIN TISSUE; CONTROLLED STUDY; DOSE RESPONSE; FATTY ACID ANALYSIS; LIPID COMPOSITION; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; RAT; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; ANTILIPEMIC AGENTS; BRAIN; CHOLESTEROL; FATTY ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEMBRANE LIPIDS; PROCETOFEN; RATS; RATS, WISTAR;

EID: 10244256480     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.204.299     Document Type: Article

References (50)

1. Alegret, M., Verd, J.C., Diaz, C., Hernandez, G., Adzet, T., Sanchez, R.M. & Laguna, L.C. (1998) Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur J. Pharmacol., 347, 283-291.
2. Augé, N., Andrieu, N., Nčgre-Salvayre, A., Thiers, J.C., Levade, T. & Salvayre, R. (1996) The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J. Biol. Chem., 271, 19251-19255.
3. Bargossi, A.M., Battino, M., Gaddi, A., Fiorella, P.L., Grossi, G., Barozzi, G., Di Giulio, R., Descovich, G., Sassi, S., Genova, M.L. & Lenaz, G. (1994) Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int. J. Clin. Lab. Res., 24, 171-176.
4. Beffert, U., Danik, M., Krzywkowski, P., Ramassamy, C., Berrada, F. & Poirier, J. (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res. Rev. 27, 119-142.
5. Bellosta, S., Bernini, F., Ferri, N., Quarato, P., Canavesi, M., Arnaboldi, L., Fumagalli, R., Paoletti, R. & Corsini, A. (1998) Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis, 137, S101-S109.
6. Broeders, N., Knoop, C., Antoine, M., Tielemans, C. & Abramowicz, D. (2000) Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol. Dial. Transplant., 15, 1993-1999.
7. Bucher, H.C., Griffith, L.E. & Guyatt, G.H. (1999) Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vasc. Biol., 19, 187-195.
8. Chatterjee, S. (1998) Sphingolipids in atherosclerosis and vascular biology. Arterioscler. Thromb. Vasc. Biol., 18, 1523-1533.
9. Colton, C.A., Brown, C.M., Cook, D., Needham, L.K., Xu, Q., Czapiga, M., Saunders, A.M., Schmechel, D.E., Rasheed, K. & Vitek, M.P. (2002) APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol. Aging, 23, 777-785.
10. De Vries, A.C. & Cohen, L.H. (1993) Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo. Biochim. Biophys. Acta 1167, 63-69.
11. Ditschunheit, H.H., Kuhn, K. & Ditschuneit, H. (1991) Comparison of different HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol., 40, S27-S32.
12. Dujovne, C.A. (1997) New lipid lowering drugs and new effects of old drugs. Curr. Opin. Lipidol., 8, 362-368.
13. Endo, A. (1992) The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 33, 1569-1582.
14. Folch, J., Lees, M. & Sloane-Stanley, G.H. (1957) A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem., 226, 497-509.
15. Frøyland, L., Madsen, L., Vaagenes, H., Totland, G.K., Auwerx, J., Kryvi, H., Staels, B. & Berge, R.K. (1997) Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J. Lipid Res., 38, 1851-1858.
16. Fujioka, T., Nara, F., Tsujita, Y., Fukushige, J., Fukami, M. & Kuroda, M. (1995) The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor, in rats. Biochim. Biophys. Acta, 1254, 7-12.
17. Gaw, A., Packard, C.J. & Shepherd, J. (1994) Fibrates. Handbook of Experimental Pharmacology. Hypolipidemic Agents. In: Principles and Treatment of Lipoprotein Disorders, edited by G. Schettler & A.J.R. Habenicht, Springer-Verlag, Berlin, p. 341.
18. Gonzalez, E.R. & Kannewurf, B.S. (1998) Atherosclerosis: a unifying disorder with diverse manifestations. Am. J. Health Syst. Pharm., 55, S4-S7.
19. Haines, T.H. & Dencher, N.A. (2002) Cardiolipin: a proton trap for oxidative phosphorylation. FEBS Lett., 528, 35-39.
20. Illingworth, D.R. & Tobert, J.A. (1994) A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther., 16 366-385.
21. Innis, S.M. (2003) Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J. Pediatr., 143, Suppl. 4, S1-S8.
22. Jick, H., Zornberg, G.L, Jick, S.S., Seshadri, S. & Drachman, D.A. (2000) Statins and the risk of dementia. Lancet, 356, 1627-1631.
23. Kannel, W.B. (1998) Overview of atherosclerosis. Clin. Ther., 20, B2-B17.
24. Kirsch, C.H., Eckert, G.P. & Mueller, W.E. (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol., 65, 843-856.
25. Krause, B.R. & Princen, H.M.G. (1998) Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis, 140, 15-24.
26. Liao, J.K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest., 110, 285-288.
27. Lipscombe, J., Lewis, G.F., Cattran, D. & Bargman, J.M. (2001) Deterioration in renal function associated with fibrate therapy. Clin. Nephrol., 55, 39-44.
28. Locatelli, S., Lütjohann, D., Schmidt, H.H.-J., Otto, C., Beisiegel, U. & von Bergmann, K. (2002) Reduction of plasma 24S-hydroxychole sterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Arch. Neurol., 59, 213-216.
29. Martin, M.J., Hulley, S.B., Browner, W.S., Kuller, L.H. & Wentworth, D. (1986) Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet, 2, 933-936.
30. Murray, C.J. & Lopez, A.D. (1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349, 1269-1276.
31. Nakahara, K., Kuriyama, M., Sonoda, Y., Yoshidome, H., Nakagawa, H., Fujiyama, J., Higuchi, I. & Osame, M. (1998) Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 152, 99-106.
32. Ness, G.C., Miller, J.P., Moffler, M.H., Woods, L.S., & Harris, H.B. (1979) Perinatal development of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in rat lung, liver and brain. Lipids, 14, 447-450.
33. Ong, W.Y., Hu, C.Y., Soh, Y.P., Lim, T.M., Pentchev, P.G., & Patel, S.C. (2002) Neuronal localization of sterol regulatory element binding protein-1 in the rodent and primate brain: a light and electron microscopic immunocytochemical study. Neuroscience, 97, 143-153.
34. Pedersen, T.R. (1998) Aggressive lipid-lowering therapy: a clinical imperative. Eur. Heart J., 19, M15-M21.
35. Pfrieger, F.W. (2002) Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes ? BioEssays, 25, 72-78.
36. Qi, K., Hall, M. & Deckelbaum, R.J. (2002) Long-chain polyunsaturated fatty acid accretion in brain. Curr. Opin. Clin. Nutr. Metabol. Care, 5, 133-138.
37. Reijneveld, J.C., Koot, R.W., Bredman, J.J., Joles, J.A. & Bar, P.R. (1996) Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res., 39, 1028-1035.
38. Saheki, A., Terasaki, T., Tamai, I. & Tsuji, A. (1994) In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res., 11, 305-311.
39. Satoh, K. & Ichihara, K. (1995) Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur. J. Pharmacol. 292, 271-275.
40. Schoonjans, K., Staels, B. & Auswerx, J. (1996) Role of the peroxisome proliferator-activated receptors (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907-925.
41. Schoonjans, K., Martin, G., Staels, B. & Auswerx, J. (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol., 8, 159-166.
42. Sgro, C. & Escousse, A. (1991) Side effects of fibrates. Therapie, 46, 351-354.
43. Staels, B. (2000) The PPAR system and regulation of lipoprotein metabolism. In: Lipids and Vascular Disease, edited by D.J. Betteridge, Martin Dunitz Ltd., London, pp. 27-37.
44. Tanaka, T. & Strauss, J.F. (1982) Stimulation of luteal mitochondrial cholesterol side-chain cleavage by cardiolipin. Endocrinology, 110, 1592-1598.
45. Tvrzická, E., Mareš, M., Votruba, M. & Hrabák, P. (1990) Some limitations of plasma lipid analysis in clinical research by thin-layer chromatography with flame ionisation detection. J. Chromatogr B., 530, 424-431.
46. Tvrzická, E., Vecka, M., Staňková, B. & Ž ák, A. (2002) Analysis of fatty acids in plasma lipoproteins by gas chromatography-flame ionisation detection. Quantitative aspects. Anal. Chim. Acta, 465, 337-350.
47. Vega, G.L., Weiner, M.E, Lipton, A.M., von Bergmann, K., Lütjohann, D., Moore, C. & Svetlik, D. (2003) Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol., 60, 510-515.
48. Vgontzas, A.N., Kales, A., Bixler, E.O., Manfredi, R.L. & Tyson, K.L. (1991) Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin. Pharmacol. Ther., 50, 730-737.
49. Wolf, R., Lo Schiavo, A., Russo, A., De Angelis, F. & Ruocco, V. (1999) Effects of gemfibrozil on in vitro cultured normal human skin explants. Int. J. Dermatol., 38, 65-69.
50. Wolozin, B., Kellman, W., Rousseau, P., Celesia, G.G. & Siegel, G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 57, 1439-1443.